Oncology ASCO 2023 – Gregory Lubiniecki With its blockbuster checkpoint inhibitor Keytruda, Merck has been a star of the show at many ASCO conferences in recent years.
News Merck rare tumour drug Ezmekly backed for NHS use Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
